New York Cancer & Blood Specialists - Eastchester Cancer Center
Bronx, NY
Accepting patients
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- CELMoD
- Randomization
- Phase 3
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3